26 / 28
CONCLUSIONS
-
Challenge
with the implementation of effective treatments for HSPC and non-metastatic CRPC
-Resistance
- Sequence
-In contrast to other tumour types,
personalized medicine is not a reality
for mCRPC yet
-Need to
identify biomarkers
and
validate
in clinical trials
-
Technical development
for ctDNA and CTC´s
-Access to sequencing. Standarization of techniques, analyses pipelines, etc…
Develop of
inmunotherapy and new drugs
to target other pathways altered in prostate cancer
- Genetics?